<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ifosfamide nephrotoxicity</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ifosfamide nephrotoxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ifosfamide nephrotoxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roderick Skinner, PhD, MBChB, FRCPCH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">Ifosfamide</a> is a synthetic structural isomer of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> that has been approved for concurrent use with other drugs in the treatment of metastatic germ-cell testicular cancer and some (especially pediatric) sarcomas.</p><p>Nephrotoxicity due to direct tubular injury is a prominent complication of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> therapy; glomerular toxicity may also occur. Issues related to ifosfamide nephrotoxicity will be reviewed here. The nephrotoxicity of other chemotherapeutic agents is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Renal toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Many in vitro studies suggest that the metabolite chloroacetaldehyde is directly toxic to the tubular cells, rather than the parent drug or another metabolite acrolein [<a href="#rid1">1-4</a>]. This relationship could explain why <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, although structurally similar to <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, has virtually no nephrotoxicity. At equivalent doses, the rate of chloroacetaldehyde generation with ifosfamide is much greater than with cyclophosphamide, although there is considerable variability from patient to patient in the amount of chloroacetaldehyde produced after ifosfamide administration [<a href="#rid1">1</a>]. Other toxic metabolites specific to ifosfamide but not cyclophosphamide, such as isophosphoramide mustard, may contribute to nephrotoxicity, although in vitro studies have given conflicting results [<a href="#rid5">5</a>]. On the other hand, acrolein is believed to be the major cause of the bladder toxicity (hemorrhagic cystitis) seen with both ifosfamide and cyclophosphamide.</p><p>The mechanism of injury remains unproven but may be cellular oxidative stress, leading to energy depletion via mitochondrial damage, a mechanism similar to that observed with the mitochondrial cytopathies [<a href="#rid4">4,6</a>]. Disruption of cell membrane function is another possible mechanism of toxicity.</p><p><a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">Mesna</a>, which is used concurrently with <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> to prevent bladder toxicity, might also be expected to reduce kidney damage due to chloroacetaldehyde or other nephrotoxic metabolites of ifosfamide. However, mesna has a complex intrarenal pharmacology and association with intratubular glutathione. Thus, it has not been possible to demonstrate a clear role for mesna in prevention of ifosfamide nephrotoxicity [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Ifosfamide-induced kidney injury is primarily manifested by the onset of one or more of the following signs of tubular dysfunction [<a href="#rid1">1,7-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypophosphatemia induced by decreased proximal tubular phosphate reabsorption; when prolonged, this can lead to rickets in children and osteomalacia in adults [<a href="#rid7">7-11,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More generalized impairment of proximal tubular function (Fanconi syndrome) as manifested by renal glucosuria, bicarbonaturia, aminoaciduria, tubular proteinuria (demonstrated by a marked increase in urinary excretion of low-molecular-weight proteins such as beta-2-microglobulin, but not of albumin), and potassium wasting (which may cause severe hypokalemia) [<a href="#rid1">1,7-9,11-13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic acidosis with a normal anion gap (hyperchloremic) acidosis due to type 1 (distal) or type 2 (proximal) renal tubular acidosis [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria due to nephrogenic diabetes insipidus (ie, resistance to antidiuretic hormone), which appears to be relatively rare [<a href="#rid8">8,10,13,14</a>]; when polyuria does occur, it is more often an appropriate response to isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> hydration therapy given during chemotherapy administration. (See <a class="local">'Etiology of polyuria'</a> below.)</p><p></p><p>The time of onset of tubular dysfunction is variable. In a report of 27 patients with manifestations of tubular dysfunction, the diagnosis was made during <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> therapy in 9 patients and after the cessation of therapy in 18 patients at a median of 13 months [<a href="#rid7">7</a>]. In addition to tubular dysfunction, ifosfamide therapy can lead to a reduction in glomerular filtration rate (GFR) [<a href="#rid8">8,9</a>]. In most patients, the decline in GFR is mild (usually no more than 20 to 30 percent below the baseline level) unless ifosfamide is given in combination with another nephrotoxin such as <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid8">8,9,13</a>]. Ifosfamide treatment has also been reported to lead to albuminuria in long-term childhood cancer survivors [<a href="#rid15">15</a>]. (See <a class="local">'Risk factors'</a> below and <a class="local">'Long-term prognosis'</a> below.)</p><p>The clinical manifestations of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity are different from the major manifestations of nephrotoxicity induced by <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. Cisplatin primarily affects the S3 segment of the proximal tubule and the distal nephron, leading to acute kidney injury and hypomagnesemia due to urinary magnesium wasting. Glucosuria and aminoaciduria can occasionally occur. (See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Etiology of polyuria</span><span class="headingEndMark"> — </span>As noted in the preceding section, <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> can induce nephrogenic diabetes insipidus. However, it is an uncommon complication that typically occurs in patients who have other signs of tubular toxicity, such as glucosuria, aminoaciduria, and hypophosphatemia [<a href="#rid14">14</a>].</p><p>A more frequent problem is the marked polyuria that may complicate the administration of high-dose ifosfamide-based chemotherapy protocols. The cause of the polyuria in almost all such cases is a sodium diuresis (not a dilute water diuresis as in diabetes insipidus) that results from the volume expansion induced by <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> therapy given to maintain a high urine output during chemotherapy administration, particularly if <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is part of the regimen. Thus, the diuresis is <strong>appropriate</strong> and resolves if sodium intake is reduced and excretion of the excess fluid is permitted. In addition, the urine osmolality tends to be similar to that of plasma, not dilute as in diabetes insipidus. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria", section on 'Solute (osmotic) diuresis'</a>.)</p><p>A confounding factor is the presence of orthostatic (postural) hypotension. Although this finding may suggest possible volume depletion, it may also be due to chemotherapy-induced autonomic neuropathy. Volume expansion may minimize orthostasis by maximizing the intravascular volume, but it also leads to persistence of the polyuria.</p><p class="headingAnchor" id="H5"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The risk factors for <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity are cumulative dose, age under four to five years, and prior or concomitant <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> therapy. Prior nephrectomy, presumably as a consequence of reduced renal excretory capacity, has also been shown to increase the risk of ifosfamide nephrotoxicity in children with cancer.</p><p class="headingAnchor" id="H6"><span class="h2">Cumulative ifosfamide dose</span><span class="headingEndMark"> — </span>Clinically significant nephrotoxicity has been described in children, mostly at a total dose above 60 g/m<sup>2</sup> [<a href="#rid7">7-9,11,13,16</a>], with severe nephrotoxicity primarily occurring at a total dose of 120 g/m<sup>2</sup> or more [<a href="#rid8">8</a>]. The signs of nephrotoxicity are initially transient but become persistent in some patients as the cumulative dose increases.</p><p>The high frequency of <strong>transient</strong> nephrotoxicity was demonstrated in a prospective study of 23 children and young adults who were treated with high-dose <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> (9 g/m<sup>2</sup> given over five days for 11 cycles at three- to six-week intervals) [<a href="#rid11">11</a>]. Acute tubular dysfunction occurred in all patients and was characterized by increases in the excretion of beta-2-microglobulin, glucose, phosphate, and amino acids. These abnormalities generally disappeared by day 0 of the next cycle. Only three patients (13 percent) developed persistent Fanconi-like syndrome or requirement for oral electrolyte (potassium and phosphate) supplementation. The cumulative dose was 70 g/m<sup>2</sup> in one and over 90 g/m<sup>2</sup> in the other two.</p><p>The differences in risk of <strong>persistent</strong> nephrotoxicity according to cumulative dose were illustrated in a series of 76 children and young adults in which grading criteria were used to define the severity of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity [<a href="#rid8">8</a>]. The criteria included the glomerular filtration rate (GFR), the renal threshold for phosphate excretion (to evaluate for phosphaturia), the serum bicarbonate concentration (to evaluate for metabolic acidosis), and the early morning osmolality (to evaluate urinary concentrating ability).</p><p>The following findings with respect to moderate and severe nephrotoxicity were noted at a median follow-up of six months:</p><p class="bulletIndent1"><span class="glyph">●</span>At a cumulative <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> dose below 84 g/m<sup>2</sup>, there were no cases of severe nephrotoxicity, and 5 of 45 (11 percent) had moderate nephrotoxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At a cumulative <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> dose 84 to 119 g/m<sup>2</sup>, 1 of 16 had severe nephrotoxicity, and 4 of 16 had moderate nephrotoxicity (6 and 25 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At a cumulative <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> dose 120 g/m<sup>2</sup> or more, 5 of 15 had severe nephrotoxicity, and 6 of 15 had moderate nephrotoxicity (33 and 40 percent, respectively).</p><p></p><p>Three large cohort studies have confirmed an association between higher cumulative <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> doses and an increased risk of glomerular impairment, measured by reduced estimated GFR [<a href="#rid15">15,17</a>] and by an increased risk of stage 3 to 5 chronic kidney disease [<a href="#rid18">18</a>].</p><p>Lower doses are safer but may occasionally be associated with persistent tubular injury. At a median follow-up of 19 months in a series of 593 children and adolescents with sarcoma who were treated with <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, the incidence of tubulopathy (defined as at least two of hypophosphatemia, glucosuria, and proteinuria on at least two examinations) was 0.4 and 6.5 percent in those exposed to an ifosfamide dose of ≤24 g/m<sup>2</sup> and between 24 to 60 g/m<sup>2</sup>, respectively [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Young children</span><span class="headingEndMark"> — </span>Children under four years of age at the time of treatment may be at increased risk of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity [<a href="#rid7">7,16</a>]. In a multivariate analysis of the above study of 593 children and adolescents, children who were less than four years of age at diagnosis had an 8.7-fold higher rate of tubulopathy, compared with an 18.6 increased risk with ifosfamide doses ≥60 g/m<sup>2</sup> [<a href="#rid7">7</a>]. A possible mechanism is increased activity in young children of CYP3A, the enzyme believed to be responsible for the generation of chloroacetaldehyde, which appears to mediate ifosfamide nephrotoxicity [<a href="#rid19">19</a>]. However, some very long-term studies have failed to show a relationship between young age and a higher risk of persistent nephrotoxicity [<a href="#rid9">9,20</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H6062849"><span class="h2">Prior nephrectomy</span><span class="headingEndMark"> — </span>A study of 120 children, 10 of whom had previously undergone nephrectomy as part of their anti-cancer treatment, found that nephrectomized children were much more likely to develop <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity [<a href="#rid21">21</a>]. Subclinical nephrotoxicity (defined by phosphaturia and aminoaciduria) and clinically evident nephrotoxicity (Fanconi syndrome) each occurred in three patients (30 percent). In contrast, in the remaining 110 children, subclinical and clinically evident nephrotoxicity occurred in 4 and 12 patients, respectively (4 and 11 percent). As suggested above, this is presumably due to reduced renal excretory capacity caused by previous nephrectomy. Although not investigated specifically in the published literature, it is likely that children with other causes of impaired kidney function will also have a higher risk of developing nephrotoxicity after ifosfamide treatment.</p><p class="headingAnchor" id="H8"><span class="h2">Prior or concomitant cisplatin therapy</span><span class="headingEndMark"> — </span>Concurrent administration of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> may have additive nephrotoxicity [<a href="#rid16">16,21-23</a>], and ifosfamide nephrotoxicity can occur at lower cumulative doses in patients with appreciable cisplatin exposure [<a href="#rid22">22</a>]. This potentiating effect may not occur in patients treated with low doses of ifosfamide (≤24 g/m<sup>2</sup>) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p><a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> is a less toxic analog of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, and it is not clear if concurrent carboplatin therapy is a risk factor for <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity", section on 'Use of cisplatin analogs'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The major method to prevent <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity is to limit the cumulative dose. Other preventative strategies, such as coadministration of <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">mesna</a> or <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC), have been evaluated, but efficacy is unproven.</p><p class="headingAnchor" id="H10"><span class="h2">Limit ifosfamide dose</span><span class="headingEndMark"> — </span>As noted above, the risk of nephrotoxicity is low at cumulative <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> doses of 60 g/m<sup>2</sup> or less and, when toxicity does occur, it is usually mild to moderate in severity and more likely to be transient [<a href="#rid8">8,9,16,20</a>]. Limiting the cumulative ifosfamide dose may be especially important in patients with additional risk factors for toxicity, such as young children (age under four years), those who have undergone prior nephrectomy or have other causes of kidney dysfunction, and those treated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h2">Therapies of unproven efficacy</span></p><p class="headingAnchor" id="H12"><span class="h3">Mesna</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">Mesna</a> is a synthetic sulfhydryl compound that can detoxify <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> metabolites. The main clinical benefit of mesna is to prevent the accumulation of the metabolite acrolein, which causes hemorrhagic cystitis. As a result, all patients treated with ifosfamide in modern chemotherapy regimens also receive mesna. (See  <a class="medical medical_review" href="/z/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients", section on 'Mesna'</a>.)</p><p>Whether the coadministration of <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">mesna</a> also reduces kidney dysfunction remains unproven [<a href="#rid1">1,24</a>]. In experimental studies, prior in vivo mesna administration did not prevent in vitro nephrotoxicity induced by chloroacetaldehyde, the metabolite that appears to be responsible for <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity [<a href="#rid24">24</a>]. It is unclear whether alternative mesna administration schedules are more likely to prevent ifosfamide nephrotoxicity. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h3">N-acetylcysteine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC), which is used in the treatment of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (paracetamol) intoxication, has been effective in an animal model for the prevention of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity [<a href="#rid25">25,26</a>]. Clinical studies in humans have not been reported.</p><p class="headingAnchor" id="H14"><span class="h1">LONG-TERM PROGNOSIS</span><span class="headingEndMark"> — </span>The long-term impact of ifosfamide-induced kidney injury in children has been addressed in a small number of studies [<a href="#rid7">7-9,13,20,27</a>]. The best long-term data following moderate <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> exposure were provided in a cross-sectional study of 183 childhood cancer survivors who had been treated with a median cumulative ifosfamide dose of 54 g/m<sup>2</sup>, with only 17 receiving more than 60 g/m<sup>2</sup>; none of the patients received concurrent therapy with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid9">9</a>].</p><p>At an average follow-up of 10 years, 90 percent had normal tubular function, and 79 percent had a normal estimated glomerular filtration rate (eGFR), defined as greater than 90 mL/min per 1.73 m<sup>2</sup>. Almost all of the abnormal findings were mild:</p><p class="bulletIndent1"><span class="glyph">●</span>All but one of the 39 patients with a reduced eGFR had a value between 60 and 89 mL/min per 1.73 m<sup>2</sup>; one patient had an eGFR of 50 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Two patients had mild hypomagnesemia</p><p class="bulletIndent1"><span class="glyph">●</span>Two patients had hypophosphatemia (although 24 percent had a reduced threshold for phosphate excretion)</p><p class="bulletIndent1"><span class="glyph">●</span>One patient had a low serum bicarbonate concentration (19 mEq/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Significant renal glucosuria was present in eight patients</p><p></p><p>Using a combined nephrotoxicity score in 81 evaluable patients, 63 percent had no nephrotoxicity, 36 percent had mild nephrotoxicity, and one percent had moderate nephrotoxicity. No patients had severe nephrotoxicity. No patient required long-term treatment with bicarbonate, phosphate, calcium, or vitamin D. In multivariate analysis, the length of follow-up and older age at diagnosis were independent predictors of a reduction in GFR. Thus, the authors concluded that ongoing evaluation for progressive nephrotoxicity is warranted.</p><p>The risk of moderate to severe chronic nephrotoxicity is higher at cumulative doses ≥84 g/m<sup>2</sup>. A smaller study of 25 children with cancer evaluated serially up until 10 years after treatment with a median cumulative dose of 106 g/m<sup>2</sup> showed persistence of glomerular impairment, with 13 percent having a GFR &lt;60 mL/min/1.73m<sup>2</sup> at 10 years, but resolution of clinically significant tubular toxicity in all affected patients within the same time frame [<a href="#rid20">20</a>]. (See <a class="local">'Cumulative ifosfamide dose'</a> above.)</p><p>There are few data on long-term kidney function in adults who have received <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>. The best data come from a retrospective cohort of 259 adults who received ifosfamide chemotherapy [<a href="#rid28">28</a>]. The mean estimated GFR fell from 82 to 67 mL/min per 1.73 m<sup>2</sup> after five years; most of this reduction occurred during the course of chemotherapy (likely reflecting acute kidney injury), although kidney function continued to decline thereafter. No patient developed end-stage kidney disease (ESKD).</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">Ifosfamide</a> is a synthetic structural isomer of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> that is used to treat metastatic germ-cell testicular cancer and some (especially pediatric) sarcomas. Nephrotoxicity due to direct tubular injury is a prominent complication of ifosfamide therapy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Kidney injury is manifested by signs of tubular dysfunction including glucosuria, aminoaciduria, tubular proteinuria (ie, increased urine excretion of low-molecular-weight proteins such as beta-2-microglobulin, but not of albumin), and rarely, polyuria due to nephrogenic diabetes insipidus. With repeated treatment and hence higher cumulative doses, patients may develop hypophosphatemia due to decreased proximal phosphate reabsorption, hypokalemia due to potassium wasting, and a normal anion gap hyperchloremic metabolic acidosis. </p><p></p><p class="bulletIndent1">In addition to tubular dysfunction, <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> can lead to a reduction in glomerular filtration rate (GFR) and to albuminuria (reflecting glomerular proteinuria). The reduction in GFR is generally mild unless ifosfamide is given in combination with another nephrotoxin such as <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Risk factors for <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity include higher cumulative dose and, to a lesser extent, younger age at treatment, prior nephrectomy (and probably other causes of kidney dysfunction), and prior or concomitant <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> therapy. Clinically significant nephrotoxicity is more likely to occur at a total dose above 60 g/m<sup>2</sup> and severe nephrotoxicity above 120 g/m<sup>2</sup>. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– The cornerstone of prevention of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity is to limit the cumulative dose. Other modalities, such as <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">mesna</a> and <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC), have not been proven to be effective. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– Limited studies suggest that the long-term prognosis of moderate <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> nephrotoxicity is good with the majority of patients recovering normal tubular function and maintaining normal or only mildly reduced GFR during the first 10 years after completing treatment. (See <a class="local">'Long-term prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993; 11:173.</a></li><li><a class="nounderline abstract_t">Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 1994; 129:170.</a></li><li><a class="nounderline abstract_t">Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001; 12:1615.</a></li><li><a class="nounderline abstract_t">Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 2006; 66:7824.</a></li><li><a class="nounderline abstract_t">Zhang J, Tian Q, Zhou S-F. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther 2006; 1:55.</a></li><li><a class="nounderline abstract_t">Rossi R. Nephrotoxicity of ifosfamide--moving towards understanding the molecular mechanisms. Nephrol Dial Transplant 1997; 12:1091.</a></li><li><a class="nounderline abstract_t">Stöhr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 2007; 48:447.</a></li><li><a class="nounderline abstract_t">Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000; 82:1636.</a></li><li><a class="nounderline abstract_t">Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 2009; 27:5350.</a></li><li><a class="nounderline abstract_t">Skinner R, Pearson AD, Price L, et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65:732.</a></li><li><a class="nounderline abstract_t">Ho PT, Zimmerman K, Wexler LH, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76:2557.</a></li><li><a class="nounderline abstract_t">Husband DJ, Watkin SW. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy. Lancet 1988; 1:1116.</a></li><li><a class="nounderline abstract_t">Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996; 348:578.</a></li><li><a class="nounderline abstract_t">Rossi R, Gödde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995; 17:551.</a></li><li><a class="nounderline abstract_t">Knijnenburg SL, Jaspers MW, van der Pal HJ, et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 2012; 7:1416.</a></li><li><a class="nounderline abstract_t">Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 1998; 101:E8.</a></li><li><a class="nounderline abstract_t">Mulder RL, Knijnenburg SL, Geskus RB, et al. Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study. Cancer Epidemiol Biomarkers Prev 2013; 22:1736.</a></li><li><a class="nounderline abstract_t">Green DM, Wang M, Krasin M, et al. Kidney Function after Treatment for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. J Am Soc Nephrol 2021; 32:983.</a></li><li><a class="nounderline abstract_t">Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 2004; 144:285.</a></li><li><a class="nounderline abstract_t">Skinner R, Parry A, Price L, et al. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer 2010; 54:983.</a></li><li><a class="nounderline abstract_t">Rossi R, Gödde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12:159.</a></li><li><a class="nounderline abstract_t">Lee BS, Lee JH, Kang HG, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001; 16:796.</a></li><li><a class="nounderline abstract_t">Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 1987; 47:1457.</a></li><li><a class="nounderline abstract_t">Yaseen Z, Michoudet C, Baverel G, Dubourg L. In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. Pediatr Nephrol 2008; 23:611.</a></li><li><a class="nounderline abstract_t">Chen N, Aleksa K, Woodland C, et al. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br J Pharmacol 2008; 153:1364.</a></li><li><a class="nounderline abstract_t">Hanly L, Rieder MJ, Huang SH, et al. N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. J Popul Ther Clin Pharmacol 2013; 20:e132.</a></li><li><a class="nounderline abstract_t">Dekkers IA, Blijdorp K, Cransberg K, et al. Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol 2013; 8:922.</a></li><li><a class="nounderline abstract_t">Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data. Eur J Cancer 2012; 48:1326.</a></li></ol></div><div id="topicVersionRevision">Topic 2383 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418231" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ifosfamide, mesna, and nephrotoxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7974492" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11461933" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885387" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ifosfamide-induced nephrotoxicity: mechanism and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical pharmacology of cyclophosphamide and ifosfamide</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198030" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nephrotoxicity of ifosfamide--moving towards understanding the molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628552" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817497" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826134" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term evaluation of Ifosfamide-related nephrotoxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2386379" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nephrotoxicity after ifosfamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625085" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2896952" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774570" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for ifosfamide nephrotoxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8570867" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Concentrating capacity in ifosfamide-induced severe renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22822016" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9606250" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064520" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33653686" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Kidney Function after Treatment for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15614250" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Renal ontogeny of ifosfamide nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20405516" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8270973" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11605785" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ifosfamide nephrotoxicity in pediatric cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3815347" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204866" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278066" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775286" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23411430" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term nephrotoxicity in adult survivors of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503397" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long term renal toxicity of ifosfamide in adult patients--5 year data.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
